Nasdaq: DFTX+4.78% 24h move
Price before$38.89Sep 11, 2026, 4:00 PM ET
First trade after$45.20Sep 14, 2026, 8:03 AM ET
24h later$40.75Sep 15, 2026, 7:48 AM ET
Complete Announced during: Premarket · announced Mon 8:02a ET (premarket); before = Fri close; first trade Mon 8:03a ET; time = SEC 8-K acceptance
Definium Therapeutics (Nasdaq: DFTX) reported topline results from a Phase 3 trial of DT120 in generalized anxiety disorder on September 14, 2026. The company said the trial met its primary endpoint.
Trial details
- Drug
- DT120
- Phase
- Phase 3
- Result
- Met endpointPanorama met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12.
- Safety
- DT120 ODT 100 μg was generally well tolerated, with most treatment-emergent adverse events (TEAEs) mild to moderate in severity, transient, and predominantly occurring on the day of dosing.
- Sponsor
- Definium Therapeutics Nasdaq: DFTX
- Dates
- Announced Sep 14, 2026, 8:02 AM ET (SEC 8-K filing time)
About this trial
This Phase 3 trial tested DT120 in Generalized Anxiety Disorder. Definium Therapeutics reported that the trial met its primary endpoint.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.